REGENXBIO Inc. (RGNX)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, REGENXBIO Inc. keeps $21 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About REGENXBIO Inc.
REGENXBIO Inc. is a NASDAQ-listed biotechnology company that develops gene therapy candidates designed to introduce genes into cells, with therapies intended to correct genetic deficiencies or prompt cells to produce therapeutic proteins or antibodies. The company generated $170.4 million in FY2025 revenue.
Today's Snapshot
Yesterday RGNX finished slightly down at 8.73.
Trading Volume
Above 10d avg 1.1M
1.4M
vs S&P 500 Today
Moderate Outperformance
+0.14%
Updated: September 10, 2026 at 12:26 UTC
Peers & Related Assets
Get premium market insights delivered directly to your inbox.